The Experts below are selected from a list of 25629 Experts worldwide ranked by ideXlab platform
Evan R Myers - One of the best experts on this subject based on the ideXlab platform.
-
cost effectiveness of sacral neuromodulation versus intravesical botulinum a toxin for treatment of refractory urge incontinence
The Journal of Urology, 2009Co-Authors: Nazema Y Siddiqui, Cindy L Amundsen, Anthony G Visco, Evan R MyersAbstract:Purpose: We determined the Cost-Effectiveness of sacral neuromodulation vs intravesical botulinum toxin A for the treatment of refractory urge incontinence.Materials and Methods: We developed a Markov decision model using a societal perspective to compare costs (2008 U.S. dollars) and effectiveness (quality adjusted life-years) of sacral nerve stimulation and botulinum toxin A. Our primary outcome was the Incremental Cost-Effectiveness Ratio, which was defined as (sacral nerve stimulation cost − botulinum toxin A cost)/(sacral nerve stimulation quality adjusted life-year − botulinum toxin A quality adjusted life-year). Sensitivity analyses were performed to assess the impact of varying efficacy, costs and adverse event rates over the range of reported values.Results: In the base case scenario sacral nerve stimulation was more expensive ($15,743 vs $4,392) and more effective (1.73 vs 1.63 quality adjusted life-years) than botulinum toxin A during a 2-year period. The Incremental Cost-Effectiveness Ratio wa...
-
cost effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence
The Journal of Urology, 2009Co-Authors: Nazema Y Siddiqui, Cindy L Amundsen, Evan R Myers, Laura J Havrilesky, Anthony G ViscoAbstract:Purpose: We assessed the Cost-Effectiveness of botulinum toxin A injection compared to anticholinergic medications for the treatment of idiopathic urge incontinence.Materials and Methods: A Markov decision analysis model was developed to compare the costs in 2008 U. S. dollars and effectiveness in quality adjusted life-years of botulinum toxin A injection and anticholinergic medications. The analysis was conducted from a societal perspective with a 2-year time frame using 3-month cycles. The primary outcome was the Incremental Cost-Effectiveness Ratio, defined as the difference in cost (botulinum toxin A cost – anticholinergic cost) divided by the difference in effectiveness (botulinum toxin A quality adjusted life-years – anticholinergic quality adjusted life-years).Results: While the botulinum strategy was more expensive ($4,392 vs $2,563) it was also more effective (1.63 vs 1.50 quality adjusted life-years) compared to the anticholinergic regimen. The calculated Incremental Cost-Effectiveness Ratio was...
-
is burch colposuspension ever cost effective compared with tension free vaginal tape for stress incontinence
American Journal of Obstetrics and Gynecology, 2007Co-Authors: Anthony G Visco, Alison C Weidner, Evan R MyersAbstract:Objective This study was undertaken to evaluate the Cost-Effectiveness of Burch colposuspension compared with tension-free vaginal tape. Study Design A Markov decision model was developed to compare costs (2005 US dollars) and effectiveness (quality-adjusted life years) of Burch and tension-free vaginal tape for stress urinary incontinence over 10 years from a health care system perspective. After surgery, outcomes included cure, persistent stress urinary incontinence followed by second surgery, and persistent stress urinary incontinence and mesh erosion after tension-free vaginal tape. An Incremental Cost-Effectiveness Ratio of less than $50,000 per quality-adjusted life year was considered cost-effective. Results For the base-case, the Burch strategy cost more than tension-free vaginal tape ($9320 vs $8081), but was slightly more effective (7.260 vs 7.248 quality-adjusted life years). The Incremental Cost-Effectiveness Ratio was $98,755 per quality-adjusted life year. The Incremental Cost-Effectiveness Ratio was less than $50,000 per quality-adjusted life year when the relative risk of cure after Burch to tension-free vaginal tape was greater than 1.09. Conclusion Burch colposuspension was not cost-effective compared with tension-free vaginal tape. However, if the tension-free vaginal tape failure rate was to increase over time, Burch may become cost-effective.
Anthony G Visco - One of the best experts on this subject based on the ideXlab platform.
-
cost effectiveness of sacral neuromodulation versus intravesical botulinum a toxin for treatment of refractory urge incontinence
The Journal of Urology, 2009Co-Authors: Nazema Y Siddiqui, Cindy L Amundsen, Anthony G Visco, Evan R MyersAbstract:Purpose: We determined the Cost-Effectiveness of sacral neuromodulation vs intravesical botulinum toxin A for the treatment of refractory urge incontinence.Materials and Methods: We developed a Markov decision model using a societal perspective to compare costs (2008 U.S. dollars) and effectiveness (quality adjusted life-years) of sacral nerve stimulation and botulinum toxin A. Our primary outcome was the Incremental Cost-Effectiveness Ratio, which was defined as (sacral nerve stimulation cost − botulinum toxin A cost)/(sacral nerve stimulation quality adjusted life-year − botulinum toxin A quality adjusted life-year). Sensitivity analyses were performed to assess the impact of varying efficacy, costs and adverse event rates over the range of reported values.Results: In the base case scenario sacral nerve stimulation was more expensive ($15,743 vs $4,392) and more effective (1.73 vs 1.63 quality adjusted life-years) than botulinum toxin A during a 2-year period. The Incremental Cost-Effectiveness Ratio wa...
-
cost effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence
The Journal of Urology, 2009Co-Authors: Nazema Y Siddiqui, Cindy L Amundsen, Evan R Myers, Laura J Havrilesky, Anthony G ViscoAbstract:Purpose: We assessed the Cost-Effectiveness of botulinum toxin A injection compared to anticholinergic medications for the treatment of idiopathic urge incontinence.Materials and Methods: A Markov decision analysis model was developed to compare the costs in 2008 U. S. dollars and effectiveness in quality adjusted life-years of botulinum toxin A injection and anticholinergic medications. The analysis was conducted from a societal perspective with a 2-year time frame using 3-month cycles. The primary outcome was the Incremental Cost-Effectiveness Ratio, defined as the difference in cost (botulinum toxin A cost – anticholinergic cost) divided by the difference in effectiveness (botulinum toxin A quality adjusted life-years – anticholinergic quality adjusted life-years).Results: While the botulinum strategy was more expensive ($4,392 vs $2,563) it was also more effective (1.63 vs 1.50 quality adjusted life-years) compared to the anticholinergic regimen. The calculated Incremental Cost-Effectiveness Ratio was...
-
is burch colposuspension ever cost effective compared with tension free vaginal tape for stress incontinence
American Journal of Obstetrics and Gynecology, 2007Co-Authors: Anthony G Visco, Alison C Weidner, Evan R MyersAbstract:Objective This study was undertaken to evaluate the Cost-Effectiveness of Burch colposuspension compared with tension-free vaginal tape. Study Design A Markov decision model was developed to compare costs (2005 US dollars) and effectiveness (quality-adjusted life years) of Burch and tension-free vaginal tape for stress urinary incontinence over 10 years from a health care system perspective. After surgery, outcomes included cure, persistent stress urinary incontinence followed by second surgery, and persistent stress urinary incontinence and mesh erosion after tension-free vaginal tape. An Incremental Cost-Effectiveness Ratio of less than $50,000 per quality-adjusted life year was considered cost-effective. Results For the base-case, the Burch strategy cost more than tension-free vaginal tape ($9320 vs $8081), but was slightly more effective (7.260 vs 7.248 quality-adjusted life years). The Incremental Cost-Effectiveness Ratio was $98,755 per quality-adjusted life year. The Incremental Cost-Effectiveness Ratio was less than $50,000 per quality-adjusted life year when the relative risk of cure after Burch to tension-free vaginal tape was greater than 1.09. Conclusion Burch colposuspension was not cost-effective compared with tension-free vaginal tape. However, if the tension-free vaginal tape failure rate was to increase over time, Burch may become cost-effective.
Harindra C Wijeysundera - One of the best experts on this subject based on the ideXlab platform.
-
a cost utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk
The Journal of Thoracic and Cardiovascular Surgery, 2018Co-Authors: Avery Hughes, Stephen E Fremes, Saerom Youn, Rebecca Hancockhoward, Peter C Coyte, Harindra C WijeysunderaAbstract:Abstract Objective Although transcatheter aortic valve implantation has been shown to be noninferior to surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk, the Cost-Effectiveness of this strategy in this population is unknown. Our objective was to conduct a cost-utility analysis comparing transcatheter aortic valve implantation with surgical aortic valve replacement in the population with intermediate risk severe aortic stenosis. Methods A fully probabilistic Markov model with 30-day cycles was constructed from the Canadian third-party payer's perspective to estimate the difference in cost and effectiveness (measured as quality-adjusted life years) of transcatheter aortic valve implantation versus surgical aortic valve replacement for intermediate-risk patients over a lifetime time horizon, discounted at 1.5% per annum. Clinical trial data from The Placement of Aortic Transcatheter Valve 2 informed the efficacy inputs. Costs (adjusted to 2016 Canadian dollars) were obtained from the Canadian Institute of Health Information and the Ontario Schedule of Benefits. Incremental Cost-Effectiveness Ratios were calculated. Results In the base-case analysis, total lifetime costs for transcatheter aortic valve implantation were $10,548 higher than surgical aortic valve replacement but added 0.23 quality-adjusted life years, for an Incremental Cost-Effectiveness Ratio of $46,083/quality-adjusted life-years gained. Deterministic 1-way analyses showed that the Incremental Cost-Effectiveness Ratio was sensitive to rates of complications and cost of the transcatheter aortic valve implantation prosthesis. There was moderate-to-high parameter uncertainty; transcatheter aortic valve implantation was the preferred option in only 52.7% and 55.4% of the simulations at a $50,000 and $100,000 per quality-adjusted life years willingness-to-pay thresholds, respectively. Conclusions On the basis of current evidence, transcatheter aortic valve implantation may be cost-effective for the treatment of severe aortic stenosis in patients with intermediate surgical risk. There remains moderate-to-high uncertainty surrounding the base-case Incremental Cost-Effectiveness Ratio.
Luca Castagna - One of the best experts on this subject based on the ideXlab platform.
-
Cost-Effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years
Bone Marrow Transplantation, 2018Co-Authors: Mathias Debals-gonthier, Carole Siani, Catherine Faucher, Rajae Touzani, Claude Lemarié-basset, Christian Chabannon, Sabine Furst, Raynier Devillier, Samia Harbi, Luca CastagnaAbstract:Due to limited donor availability, high comorbidities, and cost issues, allogeneic hematopoietic stem cell transplant is not universally accessible. The aim of this study was to conduct a Cost-Effectiveness analysis of haploidentical vs matched unrelated transplant. This retrospective study included patients with hematological malignancies older than 55 years who underwent haploidentical or matched unrelated transplant between 2011 and 2013 in Marseille. The Incremental Cost-Effectiveness Ratio has been calculated using the mean overall survival and the mean transplant costs. Costs were calculated using a micro-costing strategy from the hospital perspective and a time horizon at 2 years. Haploidentical transplant was considered an innovative procedure and matched unrelated transplant as the reference. Probabilistic and sensitivity analyses were performed on the Incremental Cost-Effectiveness Ratio. During inclusion, 29 patients underwent haploidentical transplant and 63 matched unrelated transplant. In haploidentical and matched unrelated transplant, the mean overall survival was 19.4 (1.6) months and 15.1 (1.2) months (p = 0.06), respectively, and the mean cost was 98,304 (40,872) € and 151,373 (65,742) € (p
Nazema Y Siddiqui - One of the best experts on this subject based on the ideXlab platform.
-
cost effectiveness of sacral neuromodulation versus intravesical botulinum a toxin for treatment of refractory urge incontinence
The Journal of Urology, 2009Co-Authors: Nazema Y Siddiqui, Cindy L Amundsen, Anthony G Visco, Evan R MyersAbstract:Purpose: We determined the Cost-Effectiveness of sacral neuromodulation vs intravesical botulinum toxin A for the treatment of refractory urge incontinence.Materials and Methods: We developed a Markov decision model using a societal perspective to compare costs (2008 U.S. dollars) and effectiveness (quality adjusted life-years) of sacral nerve stimulation and botulinum toxin A. Our primary outcome was the Incremental Cost-Effectiveness Ratio, which was defined as (sacral nerve stimulation cost − botulinum toxin A cost)/(sacral nerve stimulation quality adjusted life-year − botulinum toxin A quality adjusted life-year). Sensitivity analyses were performed to assess the impact of varying efficacy, costs and adverse event rates over the range of reported values.Results: In the base case scenario sacral nerve stimulation was more expensive ($15,743 vs $4,392) and more effective (1.73 vs 1.63 quality adjusted life-years) than botulinum toxin A during a 2-year period. The Incremental Cost-Effectiveness Ratio wa...
-
cost effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence
The Journal of Urology, 2009Co-Authors: Nazema Y Siddiqui, Cindy L Amundsen, Evan R Myers, Laura J Havrilesky, Anthony G ViscoAbstract:Purpose: We assessed the Cost-Effectiveness of botulinum toxin A injection compared to anticholinergic medications for the treatment of idiopathic urge incontinence.Materials and Methods: A Markov decision analysis model was developed to compare the costs in 2008 U. S. dollars and effectiveness in quality adjusted life-years of botulinum toxin A injection and anticholinergic medications. The analysis was conducted from a societal perspective with a 2-year time frame using 3-month cycles. The primary outcome was the Incremental Cost-Effectiveness Ratio, defined as the difference in cost (botulinum toxin A cost – anticholinergic cost) divided by the difference in effectiveness (botulinum toxin A quality adjusted life-years – anticholinergic quality adjusted life-years).Results: While the botulinum strategy was more expensive ($4,392 vs $2,563) it was also more effective (1.63 vs 1.50 quality adjusted life-years) compared to the anticholinergic regimen. The calculated Incremental Cost-Effectiveness Ratio was...
